Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer

Future Oncology
Camille C Gunderson, Kathleen N Moore

Abstract

Olaparib (Lynparza™; AZD2281) is a potent PARP-1 and PARP-2 inhibitor with biologic activity in ovarian cancer as well as other solid tumors. It has been tested in Phase I and II trials and has single-agent activity in both germline BRCA mutated and sporadic ovarian cancer. Phase III trials assessing the efficacy of olaparib in the maintenance setting following first line and platinum-sensitive recurrence are underway for patients with a germline BRCA mutation, given the inherent molecular compatibility with the drug's mechanism of action.

References

Feb 8, 2002·Cell·Ashok R Venkitaraman
Apr 13, 2004·Oncogene·Maria CastedoGuido Kroemer
Aug 24, 2007·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Lucio TentoriGrazia Graziani
Jun 19, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Bastiaan EversJos Jonkers
Oct 31, 2008·Proceedings of the National Academy of Sciences of the United States of America·Sven RottenbergJos Jonkers
Jun 26, 2009·The New England Journal of Medicine·Peter C FongJohann S de Bono
Oct 15, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ursula A MatulonisRichard T Penson
Jan 6, 2010·EMBO Molecular Medicine·Ana M Mendes-PereiraAlan Ashworth
Feb 6, 2010·Proceedings of the National Academy of Sciences of the United States of America·Denise Campisi HeganPeter M Glazer
Apr 22, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter C FongStan B Kaye
Oct 15, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M A Bookman
Dec 30, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C Sessa
Mar 29, 2012·The New England Journal of Medicine·Jonathan LedermannUrsula Matulonis
Aug 23, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·L C HankerUNKNOWN AGO and GINECO study group
Sep 4, 2012·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J BarinoffA du Bois
Apr 27, 2013·Archives of Gynecology and Obstetrics·Ying ChenQuan Hao
Jul 3, 2013·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Joyce F LiuUrsula A Matulonis
Aug 8, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Joo Ern AngStan B Kaye
Jan 9, 2014·CA: a Cancer Journal for Clinicians·Rebecca SiegelAhmedin Jemal
Jan 25, 2014·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Tamar SafraFranco M Muggia
Nov 5, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bella KaufmanSusan M Domchek

❮ Previous
Next ❯

Citations

Jun 9, 2016·Expert Review of Molecular Diagnostics·Marta SzajnikTheresa L Whiteside
Apr 8, 2016·Clinical Medicine Insights. Oncology·Ioannis A Voutsadakis
Jan 27, 2019·Chemistry, an Asian Journal·Kristiana T SantosoMattie S M Timmer
Sep 4, 2019·Future Oncology·Christina R WashingtonKathleen N Moore
Apr 1, 2020·British Journal of Clinical Pharmacology·Christian RolfoJudith de Vos-Geelen
Mar 17, 2019·Clinical Pharmacokinetics·Christian RolfoAlain Ravaud
Mar 21, 2019·Frontiers in Pharmacology·Wei QinHui-Ling Cao
Apr 29, 2020·Molecular Imaging and Biology : MIB : the Official Publication of the Academy of Molecular Imaging·Florian GuibbalBart Cornelissen
Sep 3, 2020·International Journal of Molecular Sciences·Giorgio CinqueLuigi E Xodo
Aug 15, 2017·AIMS Genetics·Daniel C SultanovVasily M Studitsky
Aug 26, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Wael JdeyMarie Dutreix
Apr 16, 2021·PeerJ·Zbigniew WyżewskiKrzysztof Pawłowski
Apr 19, 2021·Nuclear Medicine and Biology·Magdalena StaniszewskaWolfgang P Fendler
Jun 3, 2021·International Journal of Molecular Sciences·Theodora ManolakouDimitrios T Boumpas
Oct 19, 2017·Gynecologic Oncology·Lauren E DockeryKathleen N Moore

❮ Previous
Next ❯

Methods Mentioned

BETA
xenografts

Clinical Trials Mentioned

NCT01247168
NCT00920595
NCT01078662
NCT01081951
NCT01844986
NCT01874353
NCT01116648

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.